← Back to headlines
MacroGenics' lead program has FDA partial hold removed
MacroGenics announced that the U.S. Food and Drug Administration (FDA) has removed a partial clinical hold on its lead development program.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
